Zacks Research Issues Positive Forecast for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities research analysts at Zacks Research increased their Q4 2026 earnings estimates for Prestige Consumer Healthcare in a research note issued on Tuesday, December 23rd. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.54 for the quarter, up from their previous estimate of $1.53. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2027 earnings at $4.84 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. The company had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS.

PBH has been the topic of several other reports. Oppenheimer decreased their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 21st. Sidoti upgraded shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective on the stock in a report on Wednesday, September 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Jefferies Financial Group dropped their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $85.33.

Prestige Consumer Healthcare Stock Down 0.5%

Shares of NYSE:PBH opened at $62.34 on Wednesday. The stock’s 50-day moving average price is $60.74 and its 200-day moving average price is $67.64. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The stock has a market capitalization of $3.00 billion, a P/E ratio of 15.47, a price-to-earnings-growth ratio of 1.97 and a beta of 0.39.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the sale, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently added to or reduced their stakes in PBH. CIBC Private Wealth Group LLC increased its position in Prestige Consumer Healthcare by 142.8% in the third quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock worth $69,000 after purchasing an additional 647 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in Prestige Consumer Healthcare in the third quarter worth $329,000. Danske Bank A S purchased a new position in Prestige Consumer Healthcare in the 3rd quarter worth about $37,000. Advisory Services Network LLC bought a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at approximately $181,000. Finally, Morningstar Investment Management LLC bought a new stake in Prestige Consumer Healthcare during the 3rd quarter valued at $956,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).